

## **AusCann Completes Board Renewal with New Chairman and Independent Director Appointments**

**20 December 2019** – Leading medicinal cannabis pharmaceutical company **AusCann Group Holdings Limited** (ASX: AC8) ('AusCann' or 'the Company') announces that as part of the Board renewal process announced on 28 October 2019, the Company has appointed Mr Max Johnston and Mrs Krista Bates as Non-Executive Directors of AusCann, effective immediately.

Mr Max Johnston will also be appointed Chairman of AusCann effective from the departure of Interim Chairman Hon. Cheryl Edwardes AM on 19 January 2020.

Mr Johnston is a highly regarded health care industry director with a wealth of executive and pharmaceutical experience. He is currently a Non-Executive Director on the Boards of ASX-listed companies BARD1 Life Sciences, PolyNovo, CannPal Animal Therapeutics and Medical Developments International. Mr Johnston previously held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the world's largest medical, pharmaceutical and consumer healthcare company for 11 years.

Mrs Krista Bates brings over 18 years of expertise in the legal field and is currently a Partner at leading Western Australian law firm Lavan specialising in Corporate law and is Head of Mining & Resources.

### **AusCann Interim Chairman, Mrs Cheryl Edwardes commented:**

"AusCann is pleased to welcome Max and Krista, two highly credentialed executives to the AusCann Board. Their health care and legal experience bring a valuable and diverse set of skills to the Board as AusCann continues to deliver on its growth strategy to become a leading cannabinoid focused pharmaceutical company."

The appointments of Mr Johnston and Mrs Bates conclude the AusCann Board renewal process and the Board would like to extend its thanks to Mrs Cheryl Edwardes for her extensive and valuable contribution to AusCann since the Company's listing on the ASX, and for her assistance during the Board renewal process.

**ENDS**

This ASX announcement was authorised for release by the Board of AusCann.

### **For more information, please contact:**

#### **For Investment Enquiries**

Quentin Megson  
Chief Financial Officer  
info@auscann.com.au  
+61 8 9561 8834

#### **For Media Enquiries**

Elodie Castagna  
FTI Consulting  
elodie.castagna@fticonsulting.com  
+61 8 9321 8533

### ABOUT AUSCANN

**AusCann Group Holdings Limited** (ASX:AC8) is an Australian-based pharmaceutical company focused on the development, production, and distribution of cannabinoid-based medicines within Australia and internationally. AusCann transforms the way Medicinal Cannabis is dispensed today by making standardised dose-controlled cannabinoid-based pharmaceutical products and clinical evidence accessible to patients, physicians and healthcare providers. AusCann enables physicians to treat their patients with a reliable, stable and standardised cannabinoid-based pharmaceutical product, monitor treatment results and adjust treatment algorithms using a portfolio of products and formulations.